5-flurouracil

DRUG2 trials

Sponsors

David Bajor, MD, Janssen Research & Development, LLC

Conditions

Pancreatic CancerSquamous Cell Carcinoma of Head and Neck

Phase 1

CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer

CompletedNCT03699319

David Bajor, MDPancreatic Cancer

Start: 2018-12-07End: 2024-09-23Updated: 2025-01-23

Phase 3

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

RecruitingNCT07276399

Janssen Research & Development, LLCSquamous Cell Carcinoma of Head and Neck

Start: 2025-12-03End: 2029-06-18Target: 500Updated: 2026-08-28

Related Papers

OrigAMI-5: A randomized, phase 3 study of amivantamab plus pembrolizumab and carboplatin vs standard of care pembrolizumab plus platinum and 5-fluorouracil as first-line treatment in recurrent/metastatic head and neck cancer.

Journal of Clinical Oncology2026-05-28

A phase I/II open-label clinical trial of CPI-613 in combination with modified FOLFIRINOX in patients with locally advanced (LAPC) or borderline resectable pancreatic cancer (BRPC).

Journal of Clinical Oncology2024-06-011 citations

Repurposing the FDA-approved anthelmintic pyrvinium pamoate for pancreatic cancer treatment: study protocol for a phase I clinical trial in early-stage pancreatic ductal adenocarcinoma

BMJ Open2023-10-0111 citations

A phase II open-label study of cpi-613 in combination with modified (m)FOLFIRINOX in patients with locally advanced pancreatic cancer.

Journal of Clinical Oncology2021-05-202 citations